Keros Therapeutics Inc (KROS)

Shares of Keros Therapeutics Inc (KROS) dropped by 20.53% from $35.65 to $28.33 in the trading on Monday, December 11, 2023. The reason why KROS down today is due to the company's presentation of additional data from its Phase 2 clinical trials of KER-050. These trials target patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF). The data was shared at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held from December 9 to 12, 2023. Keros Therapeutics presented data from its Phase 2 trials of KER-050, addressing MDS and MF. Additionally, preclinical data showed the potential of KER-050 to promote erythropoiesis in an animal model of MF. The presentation also included preclinical data related to activin receptor-like kinase 2 inhibition in a mouse model of iron-refractory iron deficiency anemia. The market's reaction to these updates led to the significant decline in KROS shares. Investors will continue to watch for developments in KER-050's clinical outcomes and their impact on the company's future prospects.